CIS has implemented a process where everyone who is in position to control the content of an educational activity has disclosed all relevant financial relationships with any commercial interest, and has personally attested that these relationships will not inappropriately affect their role in the CME activity. Refusal to disclose relevant financial relationships or agree to the expectations below may disqualify you from being a part of the planning and implementation of the CME activity.

1. List the names of commercial interests (defined in the “Glossary of Term” below), with which you or your spouse/partner have, or have had, a relevant financial relationship within the past 12 months. For this purpose, all financial relationships of your spouse or partner of which you are aware are considered yours.
2. Describe what you or your spouse/partner received (example: salary, honorarium, etc). CIS does NOT want to know how much you received.
3. Describe your role

☐ There are no relationships to disclose.

☐ The following relationship(s) could represent or be perceived to represent a conflict of interest:

<table>
<thead>
<tr>
<th>Nature of Relevant Financial Relationship</th>
<th>What was received: Salary, royalty, intellectual property rights, research grant, consulting fee, speaker fee, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.</th>
<th>Role(s): Employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and ‘other activities (please specify).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spouse/Partner</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EXPECTATIONS:**

I have disclosed to CIS all relevant financial relationships, and hereby allow CIS to disclose this information to learners in print.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based and unbiased. It will promote quality or improvements in healthcare and will not promote a specific proprietary business interest of a commercial interest.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with CIS.

I understand that CIS may need to review presentations and/or content prior to the activity, and I will provide educational content and resources in advance as requested.

I understand that a CME monitor will be attending the event to ensure that all presentations are educational, and not promotional, in nature.
If I provide recommendations involving clinical medicine, they will be based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients. All scientific research relating to this CME activity in support of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection, and analysis.

If I discuss specific health care products or services, I will use generic names to the extent possible. If necessary, I will use trade names from several different companies when available.

If I discuss any product use that is off label, I will disclose that the use or indication in question is not currently approved by the FDA.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

I have disclosed all relevant financial relationships and have read and agree to all expectations listed above.

Printed Name
Signature
Date

Glossary of Terms

Commercial Interest
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial relationships
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “‘relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
Journal of Clinical Immunology
International Journal of Inborn Errors of Immunity and Related Diseases
Editor-in-Chief: Bonagura, V. - Deputy Editor-in-Chief: Casanova, J.-L.
ISSN: 0271-9142 (print version)
ISSN: 1573-2592 (electronic version)
Journal no. 10875